{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-174958","form_type":"8-K","ticker":"SLN","cik":"0001479615","company_name":"Silence Therapeutics plc","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.080469+00:00","generated_at":"2026-05-17T17:25:48.866540+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Silence Therapeutics Q2 net loss widens to $27.4M; cash $114.2M, divesiran Phase 2 on track","bullets":["Net loss of $27.4M in Q2 2025 vs $19.8M in Q2 2024; R&D expenses rose to $17.6M.","Cash and short-term investments $114.2M as of June 30, 2025; expected to fund operations into 2028.","Divesiran Phase 2 SANRECO trial >50% enrolled; on track for full enrollment by year-end 2025.","Paused Phase 1 initiation of SLN548 to prioritize extra-hepatic siRNA targeting; preclinical data promising.","Zerlasiran Phase 3 readiness activities completed; seeking partnership for Phase 3 and commercialization."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-174958","json":"https://secwatch.observer/filing/0001193125-25-174958.json","markdown":"https://secwatch.observer/filing/0001193125-25-174958.md","text":"https://secwatch.observer/filing/0001193125-25-174958.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479615/000119312525174958/0001193125-25-174958-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479615/000119312525174958/d14149d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:25:48.866540+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}